LD 1829 LR 735(04)
An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing
Fiscal Note for Senate Amendment " " to Committee Amendment "A"
Sponsor: Sen. Rotundo of Androscoggin
Fiscal Note Required: Yes
Fiscal Note
FY 2023-24 FY 2024-25 Projections  FY 2025-26 Projections  FY 2026-27
Net Cost (Savings)
General Fund $0 ($1,336,343) ($1,147,961) ($1,160,160)
General Fund $0 $0 ($1,147,961) ($1,160,160)
General Fund $0 $1,336,343 $0 $0
Other Special Revenue Funds $0 ($1,336,343) $0 $0
Fiscal Detail and Notes
This amendment removes the ongoing General Fund appropriations to the Office of Affordable Health Care beginning in fiscal year 2024-25 and replaces it with a one-time General Fund appropriation to the Office of Affordable Health Care of $1,336,343 in fiscal year 2024-25 to establish one limited-period Public Service Coordinator II position, one limited-period Planner II position and for contracts to administer the new requirements of the Maine Prescription Drug Affordability Board.

The amendment also adds a transfer of $1,336,343 from the Department of Professional and Financial Regulation, Bureau of Financial Institutions, Other Special Revenue Funds account to the Unappropriated Surplus of the General Fund.